Reflections on the Use of MAOIs
The Carlat Psychiatry Report, Volume 4, Number 11, November 2006
https://www.thecarlatreport.com/newsletter-issue/tcprv4n11/
Issue Links: Learning Objectives | Editorial Information
Jonathan Cole, MD
Professor of Psychiatry, Harvard Medical School, Senior Consultant, McLean Hospital
Dr. Cole has disclosed that he has no consultant, speaking, or grant support relationships with any commercial companies pertaining to this educational activity. He has disclosed that he owns stock in both Pfizer and Bristol-Myers Squibb. Dr. Cole has disclosed that psychostimulants and oral selegiline have not been approved by the U.S. Food and Drug Administration for use in the treatment of depression. Please consult product labeling for the approved uses. Dr. Carlat has reviewed the content of the interview and has determined that there is no commercial bias present.
Dr. Cole, you have been involved in some of the seminal research in psychopharmacology over the years, including some of the early studies of MAOIs. One of the things that I’ve heard is that the early studies of MAOIs were not very impressive. Is that true?
You can't view details of this content, please login or buy subscription here